Phase 2
Completed N=19
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Metabolic Syndrome · Seizures
Source: ClinicalTrials.gov NCT02019667 ↗
Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Change From Baseline on the Adaptive Behavior Assessment System (ABAS) Test at the End of the Study Drug and Placebo Treatment Periods — 5.2; 4.5 scores on a scale
Summary
Objective:
To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.
Study Population:
Twenty-two children and adults with SSADH deficiency.
Design:
Double-blind, cross-over, phase II clinical trial.
Outcome Measures:
The primary outcome measures for drug efficacy will be performance on neuropsychological testing and responses to parent questionnaire. The secondary outcome measure will be TMS parameters of cortical excitation and inhibition. The outcome measures for safety will include clinical examination and neuropsychological tests.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline on the Adaptive Behavior Assessment System (ABAS) Test at the End of the Study Drug and Placebo Treatment Periods |
5.2; 4.5 | — |
| SECONDARY Change From Baseline of TMS Measurement of Motor Threshold at the End of the Study Drug and Placebo Treatment Periods |
-2; -0.5 | — |
| SECONDARY Change From Baseline of TMS Measurement of Intracortical Facilitation at the End of the Study Drug and Placebo Treatment Periods |
49.9; 40.5 | — |
| SECONDARY Change From Baseline of TMS Measurement of Short Interval Intracortical Inhibition (Short ICI) at the End of the Study Drug and Placebo Treatment Periods |
35.5; -11.0 | — |
| SECONDARY Change From Baseline of TMS Measurement of Long Interval Intracortical Inhibition (Long ICI) at the End of the Study Drug and Placebo Treatment Periods |
-9.3; 0.3 | — |
| SECONDARY Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods |
0; 0; 14; 15; 4; 3 | — |
Eligibility Criteria
- INCLUSION CRITERIA
- Aged 4 years or older
- 4-hydroxybutyric aciduria (gamma-hydroxybutyric aciduria) on two separate tests
- Documented succinic semialdehyde dehydrogenase enzyme deficiency
- Patients must have clinical features consistent with SSADH deficiency including developmental delay especially deficit in expressive language, hypotonia, ataxia, seizures, and other neuropsychiatric symptoms including sleep disturbances , attention deficit, anxiety, obsessivecompulsive disorder, and autistic traits
- During the study, women of child-bearing potential must use a reliable method of birth control until one month after the final drug taper is complete.
EXCLUSION CRITERIA
- Current alcohol use (>14 drinks/wk in men and >7 drinks/wk in women or or recreational drug use
- Contraindications to MRI: metal in the body including pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have
- Claustrophobia
- Cannot lie comfortably flat on the back for up to 2h in the MRI scanner
- Patients with a history of other major medical disorders with clinical fluctuations, or requiring therapy that might affect study participation or drug response such as severe depression or psychoses, renal or hepatic disease.
- Patients requiring treatment with drugs known to affect the GABAergic system, including vigabatrin and benzodiazepines.
- Pregnant and lactating women
Data sourced from ClinicalTrials.gov (NCT02019667). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.